Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia

Blood Reviews

Volumn 14, Issue 3, 2000, Pages 121-129

  Mesa, R A ^a   Elliott, M A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; PREDNISONE; VINCRISTINE;

BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HEPATOMEGALY; HUMAN; IMMUNOTHERAPY; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SURVIVAL; THROMBOCYTHEMIA; THROMBOCYTOSIS;

EID: 0033801381     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2000.0132     Document Type: Review

References (93)

1. The pathogenesis of myeloproliferative syndromes
2. Some speculations on the myeloproliferative syndromes
3. The spectrum of myeloproliferative disorders
4. Myelofibrosis with myeloid metaplasia
5. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
6. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
7. The spleen and pooling of blood cells
8. Physiology of the spleen and the role of splenectomy in hematologic disorders
9. Disorders of the spleen
10. Extramedullary haemopoiesis in fetal and adult human spleen: A quantitative immunohistological study
11. The spleen in myeloproliferative disorders
12. Idiopathic myelofibrosis: Pathogenesis, natural history and management
13. Indications for and results of splenectomy in different hematological disorders
14. Chronic myeloid leukemia
15. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
16. Splenic function in chronic myelogenous leukemia
17. Splenectomy in chronic non-leukemic myeloid splenomegaly with report of case with osteosclerosis
18. Cytogenetic evidence for splenic origin of blastic transformation in chronic myeloid leukaemia
19. Removal of abnormal clone of leukaemic cells by splenectomy
20. Chronic granulocytic leukaemia: Effect of elective splenectomy on the course of disease
21. Response of chronic myelogenous leukemia patients to COAP-splenectomy. A Southwest Oncology Group study
22. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogeneous leukemia
23. Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia
24. Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: A single-institution, 25-year experience
25. Chromosome changes and splenectomy in Ph1-positive chronic myeloid leukemia. I. Predictive parameters in the blastic phase
26. Related donor marrow transplant for chronic myeloid leukemia: Patient characteristics predictive of outcome
27. No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia: Results of a prospective randomized study
28. The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation
29. Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: The influence of previous splenectomy
30. Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia
31. A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia
32. Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia
33. Splenectomy in the chronic myeloproliferative syndromes. A retrospective risk-versus-benefit analysis
34. The dangers of surgery in uncontrolled haemorrhagic thrombocythaemia
35. Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis
36. The evolution into and the treatment of late stage polycythemia vera
37. Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis-a histomorphometric study on sequential trephine biopsies
38. Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis
39. Splenic hematopoiesis in polycythemia vera. A morphologic and immunohistologic study
40. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system
41. Identification of 'short-lived' and 'long-live' patients at presentation of idiopathic myelofibrosis
42. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study
43. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study, 1976-1995
44. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival
45. Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy
46. Treatment of agnogenic myeloid metaplasia with danazol: A report of four cases
47. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): A concise update
48. Management of myelofibrosis with intermittent hydroxyurea
49. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia
50. Chronic non-leukaemic myelosis
51. Splenectomy for myeloid metaplasia of the spleen
52. Splenectomy for agnogenic myeloid metaplasia
53. Splenectomy in myelofibrosis
54. Splenectomy and myelofibrosis
55. Splenectomy in myelofibrosis and myeloid metaplasia
56. Sex, splenectomy, and myeloid metaplasia
57. Indications for splenectomy in the anemic forms of myelofibrosis with myeloid metaplasia of the spleen
58. Splenectomy for massive splenomegaly due to myeloid metaplasia
59. Splenectomy for hematologic disorders
60. Subtotal splenectomy in myelofibrosis
61. Clinical course and survival after elective splenectomy in 19 patients with primary myelofibrosis
62. Splenectomy in myeloid metaplasia
63. Splenectomy in patients with agnogenic myeloid metaplasia: An analysis of 321 published cases
64. Splenectomy in myeloid metaplasia
65. Polycythemia vera with myelofibrosis and myeloid metaplasia. Acute hepatic failure following splenectomy
66. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia
67. 'Early' splenectomy and survival in agnogenic myeloid metaplasia. An analysis of 338 cases published since 1940
68. Splenectomy for hematologic disease
69. Splenectomy for agnogenic myeloid metaplasia
70. Splenectomy for myelofibrosis
71. Splenectomy in primary myelofibrosis: Two long-term survivors after splenectomy
72. Hypersplenism and splenectomy in lymphoproliferative and myeloproliferative disorders
73. Increased platelet aggregation following splenectomy in patients with myeloproliferative disease
74. Splenectomy for myeloproliferative disorders
75. Effect of splenectomy on circulating haematopoietic progenitors in myelofibrosis
76. Early postoperative course following elective splenectomy in haematological diseases: A high complication rate in patients with myeloproliferative disorders
77. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases
78. Splenectomy for thrombocytopenia due to secondary hypersplenism
79. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia
80. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia
81. Massive hepatomegaly following splenectomy for myeloid metaplasia. Case report and review of the literature
82. Liver dysfunction following splenectomy in idiopathic myelofibrosis: A study of 10 patients
83. A prognostic classification of myelofibrosis with myeloid metaplasia
84. Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients
85. Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction
86. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients
87. Splenectomy in Hodgkin's disease and second leukaemias
88. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease
89. Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen?
90. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party
91. Splenectomy in agnogenic myeloid metaplasia
92. Clinical correlates of splenic histopathology in myelofibrosis with myeloid metaplasia
93. Risks and benefits of splenectomy in myelofibrosis: An analysis of 39 cases